Life Sciences Blog

Japanese drugmaker Otsuka to buy U.S. cancer firm Astex for $886M

Posted on September 6th, by Michael Shapiro-Barr

Japan’s drugmaker Otsuka Holdings Co. has agreed to buy Astex Pharmaceuticals Inc., a U.S. cancer drug biotechnology company, for $886 million.  The deal comes as many large pharmaceutical companies facing patent expiration, creating the need to gain access to new drugs to increase income.

Read More 



Comments are closed.

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Media Quotes

  • Mercedes Meyer, a patent lawyer with the firm Drinker Biddle in Washington, D.C., said the Supreme Court’s failure to provide “bright-line guidance”—a ruling that would settle once-and-for all whether patent settlements are legal or not—means there’s “really no difference now than what was going on.” Mercedes Meyer
    CNBC: High Court Allows FTC to Challenge 'Pay-to-Delay' Generics

From the Blog

Photocopiers – A Recurring Data Security Risk

In a case that illustrates the data privacy risks associated with modern copiers, the United States Department of Health and Human Resources (HHS) has...

FDA and CBP to Begin New Pilot Programs

Both the Food and Drug Administration (FDA) and U.S. Customs and Border Protection (CBP) are expected to begin pilot programs to give additional benefits...

Ethical Issues Surrounding Noncompliance in Organ Donation

Within a few months of the controversial lung donation to a child who was placed on the adult organ donation waiting list by way...